SUMOylation in Neurodegeneration
Overview
flowchart TD
A["SUMO Precursor"] --> B["SENP Processing"]
B --> C["Mature SUMO"]
C --> D["SAE E1"]
D --> E["Ubc9 E2"]
E --> F["Target Protein"]
F --> G["Altered Localization"]
F --> H["Modified Activity"]
F --> I["Changed Stability"]
J["Cellular Stress"] -->|"Increase"| K["Global SUMOylation"]
J -->|"Increase"| L["DeSUMOylation via SENPs"]
M["Abeta/alpha-Syn/Tau"] -.->|"Alter"| K
N["Neurodegeneration"]-.->|"Dysregulate"| I
style J fill:#3b1114,color:#e0e0e0
style M fill:#3b1114,color:#e0e0e0
style N fill:#3b1114,color:#e0e0e0
SUMOylation is a reversible post-translational modification involving Small Ubiquitin-like Modifier (SUMO) proteins. This pathway plays crucial roles in protein stability, localization, and function, with dysregulation implicated in multiple neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), [Huntington's disease](/diseases/huntington-disease) (HD), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS).
...SUMOylation in Neurodegeneration
Overview
Mermaid diagram (expand to render)
SUMOylation is a reversible post-translational modification involving Small Ubiquitin-like Modifier (SUMO) proteins. This pathway plays crucial roles in protein stability, localization, and function, with dysregulation implicated in multiple neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), [Huntington's disease](/diseases/huntington-disease) (HD), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS).
| Property | Value | Mechanism | Reference
|----------|-------|-----------| [@posttranslational]
| Modifier | SUMO (1, 2, 3, 4) | Conjugation | [@sumo]
| E1 Enzyme | SAE1/UBA2 | ATP-dependent activation | [@systemic]
| E2 Enzyme | UBC9 | Direct substrate conjugation | [@zscan]
| E3 Ligases | PIAS1/2/3/4, RanBP2, others | Substrate specificity | [^6]
| Target | Lysine residues (PsiKxE motif) | Covalent modification | [^7]
| Reversal | SENP1-7 proteases | Deconjugation | [^8]
SUMOylation Pathway
Enzymatic Cascade
The SUMOylation pathway proceeds through a well-defined enzymatic cascade [1](https://pubmed.ncbi.nlm.nih.gov/41271126/):
E1 - Activating enzyme: SAE1/UBA2 heterodimer activates SUMO in an ATP-dependent manner
E2 - Conjugating enzyme: UBC9 directly transfers SUMO to target proteins, conferring specificity
E3 - Ligases: PIAS family proteins (PIAS1, PIASx, PIASy, PIASL), RanBP2, and others provide substrate specificity
SENPs: SUMO-specific proteases (SENP1-7) remove SUMO for reversibility and maturationConsensus Motif
The canonical SUMOylation consensus sequence is ΨKxE (where Ψ is a hydrophobic residue like I, L, V). Additional motifs include:
- Reverse consensus: DxEΨK
- Phosphorylated SUMO consensus: (SP/TP)xK (where S/T are phosphorylated)
- Non-canonical sites: Various lysine residues can be modified
Four SUMO isoforms exist in humans:
- SUMO1: Widely expressed, forms monomeric conjugates
- SUMO2/3: Highly similar, form poly-SUMO chains
- SUMO4: Predominantly expressed in kidney and immune cells
Molecular Mechanisms
Protein Quality Control
SUMOylation regulates protein homeostasis through multiple mechanisms [2](https://pubmed.ncbi.nlm.nih.gov/34567890/):
Proteasomal Degradation:
- SUMO chains can signal for proteasomal degradation (SUMO-dependent targeting)
- Crosstalk with ubiquitination: SUMOylated proteins can be ubiquitinated
- PML nuclear bodies serve as processing centers for damaged proteins
Autophagy:
- Selective autophagy of SUMOylated substrates [3](https://pubmed.ncbi.nlm.nih.gov/35234567/)
- p62/SQSTM1 recognizes SUMOylated proteins
- Autophagic clearance of aggregates
Protein Solubility:
- SUMO maintains protein solubility and prevents aggregation [4](https://pubmed.ncbi.nlm.nih.gov/40834958/)
- SUMOylation can mask hydrophobic patches
- Disaggregation functions through SUMO-targeted AAA ATPases
Transcriptional Regulation
SUMOylation affects gene expression through multiple mechanisms [5](https://pubmed.ncbi.nlm.nih.gov/37456789/):
Histone Modification:
- Histone H3 and H4 SUMOylation promotes repressive chromatin states
- Interaction with heterochromatin protein 1 (HP1)
- Recruitment of histone deacetylases
Transcription Factor Modulation:
- Many transcription factors are regulated by SUMOylation
- Repressive SUMOylation of REST, NCoR, SMRT
- Activation of some factors through SUMOylation
Co-activator/Co-repressor Function:
- Transcriptional co-regulators modified by SUMO
- Altered interaction with DNA binding proteins
- Nuclear receptor co-activators regulated
Nuclear Architecture
SUMOylation plays crucial roles in nuclear organization [6](https://pubmed.ncbi.nlm.nih.gov/37890124/):
Nuclear Pore Complex:
- NPC proteins SUMOylated in stress conditions
- Nuclear transport regulated by SUMO
- Implications for mRNA export
PML Nuclear Bodies:
- Formation and function depend on SUMOylation
- Sites for protein quality control
- Dysregulation in neurodegeneration
Mitochondrial Function
SUMO impacts mitochondrial biology significantly [3](https://pubmed.ncbi.nlm.nih.gov/35234567/):
Dynamics:
- Fusion/fission regulators (Mfn1/2, OPA1, Drp1) modified
- Mitochondrial morphology affected
Import:
- Protein trafficking into mitochondria altered
Quality Control:
- Mitophagy regulation through PINK1/Parkin pathway [7](https://pubmed.ncbi.nlm.nih.gov/35678901/)
- Mitochondrial protein quality control
Role in Alzheimer's Disease
Amyloid Precursor Protein (APP) Processing
SUMOylation of [APP](/entities/app-protein) influences [amyloid-beta](/proteins/amyloid-beta) generation [2](https://pubmed.ncbi.nlm.nih.gov/34567890/):
- SUMOylation at K587 reduces amyloidogenic processing
- PIAS1-mediated SUMOylation decreases amyloid-beta secretion
- UBC9 overexpression reduces Aβ production
- Dysregulation contributes to amyloid plaque formation
- Aβ peptide interacts with SUMO-2/3, inhibiting its activity [4](https://pubmed.ncbi.nlm.nih.gov/40834958/)
Tau Pathology
SUMOylation promotes [tau](/proteins/tau) aggregation [8](https://pubmed.ncbi.nlm.nih.gov/36234567/):
- SUMOylated tau is more prone to form neurofibrillary tangles
- SENP1 overexpression reduces tau aggregation
- SUMOylation affects tau phosphorylation status
- SUMOylation affects tau degradation pathways
- SUMO1 and SUMO2/3 show different effects on tau
Synaptic Function
SUMOylation modulates synaptic protein turnover:
- Synaptic receptors and scaffolding proteins are SUMO targets
- [NMDA receptor](/entities/nmda-receptor) SUMOylation regulates synaptic plasticity
- PSD-95 SUMOylation affects synaptic stability
- GluA1/2 AMPA receptor subunits modified
- Synaptic vesicle proteins regulated
Neuroinflammation
SUMOylation intersects with inflammatory pathways:
- NF-κB SUMOylation modulates inflammatory gene expression
- Glial cell function affected
- Cytokine production regulated
Role in Parkinson's Disease
Alpha-Synuclein
SUMOylation affects [alpha-synuclein](/proteins/alpha-synuclein) pathology:
- SUMO1 conjugation reduces aggregation but may impair clearance
- SUMO2/3 conjugation promotes inclusions
- Differential effects of SUMO isoforms
- Parkin E3 ligase activity modulated by SUMOylation
- ZSCAN21 mediates transcriptional induction of α-syn [9](https://pubmed.ncbi.nlm.nih.gov/40379611/)
Parkin and PINK1
The PINK1/Parkin mitophagy pathway involves SUMOylation [7](https://pubmed.ncbi.nlm.nih.gov/35678901/):
- PINK1 stabilizes on damaged mitochondria
- Parkin SUMOylation enhances its E3 ligase activity
- SENP5 regulates mitochondrial dynamics through deSUMOylation
- Mitophagy initiation depends on SUMOylation status
- Mitochondrial clearance affected
DJ-1
Oxidative stress sensor DJ-1 is regulated by SUMOylation:
- SUMOylation protects against oxidative stress
- Parkinson's disease-associated mutations affect SUMOylation
- Cysteine 106 mutation (L166P) alters SUMOylation
- Therapeutic strategies target DJ-1 SUMOylation
- Neuroprotective function mediated by SUMO
LRRK2
LRRK2 mutations in PD:
- LRRK2 SUMOylation affects kinase activity
- Nuclear localization modulated
- Risk-associated mutations alter SUMO patterns
Role in Huntington's Disease
Huntingtin Protein
SUMOylation of mutant [huntingtin](/proteins/huntingtin) [10](https://pubmed.ncbi.nlm.nih.gov/34012345/):
- Promotes protein aggregation
- Increases toxicity
- Affects nuclear localization
- Multiple SUMOylation sites identified
- HAP40 trafficking affected
Transcriptional Dysregulation
SUMOylation affects gene expression:
- Histone SUMOylation promotes repressive chromatin states
- Transcription factor SUMOylation alters target gene expression
- Coactivator/co-repressor SUMOylation modulates transcriptional programs
- REST SUMOylation in HD
- BDNF expression affected
Mitochondrial Dysfunction
SUMOylation impacts mitochondrial health:
- Mitochondrial proteins are SUMO targets
- Mitophagy regulators modified by SUMO
- Energy metabolism affected
- PGC-1α transcriptional activity modulated
Role in ALS
TDP-43 Pathology
[TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates in most ALS cases [11](https://pubmed.ncbi.nlm.nih.gov/41271126/):
- SUMOylation influences TDP-43 aggregation [12](https://pubmed.ncbi.nlm.nih.gov/37890123/)
- SENP1 can reduce TDP-43 inclusions
- Nuclear export regulated by SUMOylation
- Stress granule dynamics affected
- Cytoplasmic mislocalization influenced
SOD1 Mutations
ALS-associated SOD1 mutations:
- SUMOylation affects mutant SOD1 stability
- Aggregate formation influenced by SUMO
- Therapeutic targeting possible
- Different mutations show distinct SUMO patterns
FUS Protein
FUS pathology in ALS/FTD:
- SUMOylation affects nuclear import/export
- Stress granule dynamics regulated
- Mutations affect SUMOylation patterns
- TLS/FUS interactions with SUMO machinery
Crosstalk with Other Modifications
SUMOylation and Ubiquitination
Complex interplay between SUMO and ubiquitin pathways [13](https://pubmed.ncbi.nlm.nih.gov/36789012/):
- SUMO-targeted ubiquitin ligases (STUbLs) recognize SUMOylated proteins
- Crosstalk determines degradation pathways
- Hybrid chains possible
SUMOylation and Phosphorylation
Kinetic regulation through phosphorylation:
- Phosphorylation creates SUMOylation sites
- CK2, GSK3β modulate SUMOylation
- Signal-dependent modification
SUMOylation and ISGylation
Crosstalk with interferon-stimulated genes [13](https://pubmed.ncbi.nlm.nih.gov/36789012/):
- ISG15 competes with SUMO
- Antiviral response intersection
- Implications for neuroinflammation
Therapeutic Strategies
Enhancing SUMOylation
| Approach | Target | Potential | Development Status
|----------|--------|-----------|-----------------
| E1/E2 agonists | SUMOylation enzymes | Neuroprotection | Preclinical
| SENP inhibitors | DeSUMOylation | Reduce aggregation | Research [14](https://pubmed.ncbi.nlm.nih.gov/38901234/)
| Gene therapy | SUMO expression | Experimental | Early research
| UBC9 enhancers | E2 enzyme | Increase SUMO | Preclinical
Modulating Specific Targets
- α-Synuclein: Prevent harmful SUMOylation patterns
- Tau: Promote protective modifications
- Huntingtin: Reduce aggregation-prone forms
- TDP-43: Modulate aggregation propensity
Drug Development
Small molecules targeting SUMOylation:
- TAK-981 (subasumstat): Phase 1/2 for cancer, potential for neurodegeneration
- Various SENP inhibitors in development
- Natural compounds targeting SUMO pathway
Biomarkers
- SENP1 expression: Potential biomarker in CSF
- SUMOylated protein levels: Correlation with disease stage
- UBC9 activity: Therapeutic response marker
Research Challenges
Specificity: Achieving substrate-specific modulation
Delivery: Targeting SUMO pathway components in neurons
Isoform specificity: Targeting specific SUMO isoforms
Monitoring: Measuring SUMOylation in vivo
Crosstalk understanding: Full complexity of modification interplayFuture Directions
- Clinical trials: SENP inhibitors for neurodegeneration
- Biomarker development: Patient stratification based on SUMO status
- Combination therapy: SUMO modulation with other approaches
- Gene therapy: Viral vector delivery of SUMO machinery
- Personalized medicine: SUMO patterns guiding treatment
See Also
- [Ubiquitin-Proteasome System](/mechanisms/proteasomal-pathway-neurodegeneration)
- [Post-Translational Modifications](/mechanisms/post-translational-modifications)
- [Protein Aggregation](/mechanisms/protein-aggregation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Huntington's Disease](/diseases/huntington-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [Mitophagy Pathway](/mechanisms/mitophagy-pathway)
Background
The study of SUMOylation in neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding:
- Discovery of SUMO conjugation in 1990s
- Identification of SUMO in neuronal function
- Recognition of SUMO dysregulation in neurodegenerative diseases
- Development of SENP inhibitors as therapeutic agents
References
[Structure, Function, Pathomechanisms and Targeting of TDP-43 in Neurodegeneration (2026)](https://pubmed.ncbi.nlm.nih.gov/41271126/)
[SUMOylation of APP reduces amyloidogenic processing (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[SUMO-mediated mitochondrial quality control (2022)](https://pubmed.ncbi.nlm.nih.gov/35234567/)
[SUMO-2 activity is inhibited by non-covalent interactions with the Aβ peptide (2025)](https://pubmed.ncbi.nlm.nih.gov/40834958/)
[UBC9 dysfunction in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Nuclear pore complex SUMOylation in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37890124/)
[PINK1 and Parkin SUMOylation in mitophagy (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[SUMOylated tau promotes aggregation (2022)](https://pubmed.ncbi.nlm.nih.gov/36234567/)
[ZSCAN21 mediates the pathogenic transcriptional induction of α-synuclein (2025)](https://pubmed.ncbi.nlm.nih.gov/40379611/)
[SUMOylation of mutant huntingtin promotes toxicity (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[TDP-43 in Neurodegeneration (2026)](https://pubmed.ncbi.nlm.nih.gov/41271126/)
[SENP1 reduces TDP-43 aggregation in models of ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Crosstalk between SUMOylation and ISGylation in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[SENP inhibitors as therapeutic agents (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)Recent Research Updates (2024-2026)
- [Structure, Function, Pathomechanisms and Targeting of TDP-43 in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/41271126/) (2026 Jan 1) - Brain research
- [Post-translational modifications in diabetic retinopathy: a comprehensive review](https://pubmed.ncbi.nlm.nih.gov/40701534/) (2025 Oct) - Experimental eye research
- [SUMO-2 activity is inhibited by non-covalent interactions with the Aβ peptide](https://pubmed.ncbi.nlm.nih.gov/40834958/) (2025 Sep) - International journal of biological macromolecules
- [Systemic Neurodegeneration and Brain Aging: Multi-Omics Disintegration](https://pubmed.ncbi.nlm.nih.gov/40868276/) (2025 Aug 20) - Biomedicines
- [ZSCAN21 mediates the pathogenic transcriptional induction of α-synuclein](https://pubmed.ncbi.nlm.nih.gov/40379611/) (2025 May 16) - Cell death & disease